TheraRadar
Clinical-Stage Companies / Trevi

Trevi

Pre-Approval PRO BETA
16
Total Trials
6
Phase 3
9
Phase 2
2
Recruiting
200
Score

Pipeline by Phase

Phase 3
6
Phase 2
9
Phase 1
6

Therapeutic Focus

Idiopathic Pulmonary Fibrosis Prurigo Nodularis Uremic Pruritus Pruritus Refractory Chronic Cough

Clinical Trials (16)

NCT07671911 Phase 3 NOT YET RECRUITING

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Started: 6/1/2026

NCT05962151 Phase 2 COMPLETED

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

Started: 11/30/2023

NCT05964335 Phase 2 COMPLETED

Cough Reduction in IPF With Nalbuphine ER

Started: 2/6/2024

NCT03497975 Phase 2 COMPLETED

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

Started: 8/7/2018

NCT04030026 Phase 2 COMPLETED

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Started: 10/29/2019

NCT02174419 Phase 2 COMPLETED

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Started: 3/1/2015

NCT02174432 Phase 2 COMPLETED

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Started: 8/15/2015

NCT02143973 Phase 2 COMPLETED

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

Started: 9/1/2014

NCT02143648 Phase 2 COMPLETED

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Started: 6/1/2014

NCT07671924 Phase 2 NOT YET RECRUITING

The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

Started: 6/1/2026

NCT07036029 Phase 1 RECRUITING

NAL ER IPF Respiratory Function and Safety Study

Started: 8/21/2025

NCT07487740 Phase 1 RECRUITING

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

Started: 2/27/2026

NCT04020016 Phase 1 COMPLETED

Study of Nalbuphine ER in Participants With Hepatic Impairment

Started: 6/12/2019

NCT07015398 Phase 1 COMPLETED

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Started: 6/30/2025

NCT02373215 Phase 1 COMPLETED

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Started: 4/1/2013

NCT04018664 Phase 1 COMPLETED

Oral Abuse Potential Study of Nalbuphine

Started: 5/29/2018

Drug Candidates

NAL ER Nalbuphine ER Nalbuphine ER Tablets Nalbuphine HCL ER nalbuphine HCl ER tablets 90 mg BID nalbuphine HCl ER tablets 180 mg BID nalbuphine HCl ER nalbuphine HCl ER tablets 60 mg BID nalbuphine HCl ER tablets 120mg BID Nalbuphine HCl solution
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 9/26/2025
Trials (12 months): 4
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.